The kidney triggers graft-versus-host disease in experimental combined transplantation of kidney and stem cell-enriched peripheral leukocytes

Journal of the American Society of Nephrology

Volumn 7, Issue 10, 1996, Pages 2254-2258

  Perico, Norberto ^a,b   Amuchastegui, Susanna ^b   Bontempelli, Mario ^a   Remuzzi, Giuseppe ^a,b  

^a OSPEDALI RIUNITI   (Italy)

^b MARIO NEGRI INST PHARMACOL RES   (Italy)

Author keywords

GVHD; Kidney allograft; Rat; Stem cells

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHIMERA; CONTROLLED STUDY; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HISTOPATHOLOGY; KIDNEY TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION;

EID: 0030405111     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/asn.v7102254     Document Type: Article

References (25)

1. Starzl T, Demetris AJ, Murase N, Ildstad S, Ricordi C, Trucco M: Cell migration, chimerism, and graft acceptance. Lancet 1992;339:1579-1582.
2. Starzl T, Demetris AJ, Murase N, Thomson AW, Trucco M, Ricordi C: Donor cell chimerism permitted by immunosuppressive drugs: A new view of organ transplantation. Immunol Today 1993;14:326-332.
3. Kashiwagi N, Porter KA, Penn I, Brettschneider I, Starzl TE: Studies of homograft sex and of gamma phenotypes after orthotopic homotransplantation of the human liver. Surg Forum 1969;20:374-376.
4. Starzl TE, Demetris AJ, Trucco M, et al.: Systemic chimerism in human female recipients of male livers. Lancet 1992;340:876-877.
5. Starzl TE: Cell migration and chimerism: A unifying concept in transplantation with particular reference to HLA matching and tolerance induction. Transplant Proc 1993;25:8-12.
6. Fontes P, Rao AS, Demetris AJ, et al.: Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet 1994; 344:151-155.
7. Barber WH, Mankin JA, Laskow DA, et al.: Long-term results of a controlled prospective study with transfusion of donor-specific bone marrow in 57 cadaveric renal allograft recipients. Transplantation 1991;51:70-75.
8. Murase N, Demetris AJ, Fujisaki S, Tanabe M, Todo S, Starzl TE. Bone marrow augmentation for heart, liver, and small bowel transplantation: Prolongation of graft survival and incidence of GVHD [Abstract]. Kyoto, Japan: 15th World Congress of the Transplantation Society; 1994:A366.
9. Vogelsang GB, Hess AD: Graft-versus-host disease: New direction for a persistent problem. Blood 1994;84:2061-2067.
10. Goldman J: Peripheral blood stem cells for allografting. Blood 1995;85:1413-1415.
11. Chao NJ, Schriber JR, Grimes K, et al.: Granulocyte colony-stimulating factor "mobilized" peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 1993;81: 2031-2035.
12. Perico N, Imberti O, Bontempelli M, Remuzzi G: Toward novel antirejection strategies: In vivo immunosuppressive properties of CTLA4Ig. Kidney Int 1995;47:241-246.
13. Linsley PS, Brady W, Grosmaire L, Aruffo A, Damle NK, Ledbetter JA: Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin-2 mRNA accumulation. J Exp Med 1991;173:721-730.
14. Demetris AJ, Murase N, Fujisaki S, Fung JJ, Rao AS, Starzl TE: Hematolymphoid cell trafficking, microchimerism, and GVH reactions after liver, bone marrow, and heart transplantation. Transplant Proc 1993;25: 3337-3344.
15. Murase N, Demetris AJ, Woo J, et al.: Graft-versus-host disease after Brown-Norway-to-Lewis and Lewis-to-Brown Norway rat intestinal transplantation under FK506. Transplantation 1993;55:1-7.
16. Sayegh MH, Fine NA, Smith JL, Rennke HG, Milford EL, Tilney NL: Immunologic tolerance to renal allografts after bone marrow transplants from the same donors. Ann Intern Med 1991;114:954-955.
17. Steinman RM, Young JW: Signals arising from antigen-presenting cells. Curr Opin Immunol 1991;3:361-372.
18. June CH, Bluestone JA, Nadler LM, Thompson CB: The B7 and CD28 receptor families. Immunol Today 1994; 15:321-331.
19. Ledbetter JA, Imboden JB, Schieven GL, et al.: CD28 ligation in T-cell activation: Evidence for two signal transduction pathways. Blood 1990;75:1531-1539.
20. Linsley PS, Brady W, Grosmaire L, Ledbetter JA, Damle N: CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991;174:561-569.
21. Tan P, Anasetti C, Hansen JA, et al.: Induction of alloantigen specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB-1. J Exp Med 1993;177:165-173.
22. Turka LA, Linsley PS, Lin H, et al.: T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci USA 1992;89: 11102-11105.
23. Lin H, Bolling SF, Linsley PS, et al.: Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J Exp Med 1993;178:1801-1806.
24. Wallace PM, Johnson JS, MacMaster JF, Kennedy KA, Gladstone P, Linsley PS: CTLA4Ig treatment ameliorates the lethality of murine graft-versus-host disease across major histocompatibility complex barriers. Transplantation 1994;58:602-610.
25. Blazar BR, Taylor PA, Linsley PS, Vallera DA: In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice. Blood 1994;83:3815-3825.